-+ 0.00%
-+ 0.00%
-+ 0.00%

Lundbeck announces press release availability on Lu AH69593 FDA Fast Track designation for narcolepsy

PUBT·07/23/2026 07:13:51
Listen to the news
Lundbeck announces press release availability on Lu AH69593 FDA Fast Track designation for narcolepsy
  • Lundbeck published a release stating the FDA granted Fast Track designation for Lu AH69593 to treat narcolepsy.
  • Lu AH69593 is an oral orexin 2 receptor agonist in Phase 1b development.
  • Release dated July 23, 2026: link.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.